| Revision as of 14:00, 24 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit | Revision as of 22:45, 5 December 2011 edit undo70.137.157.59 (talk) cite pmidNext edit → | ||
| Line 48: | Line 48: | ||
| | StdInChIKey = IHLAQQPQKRMGSS-UHFFFAOYSA-N | | StdInChIKey = IHLAQQPQKRMGSS-UHFFFAOYSA-N | ||
| }} | }} | ||
| '''Oxiracetam''' is a ] drug of the ] family.<ref> | |||
| '''Oxiracetam''' is a ] drug of the ] family.<ref>{{cite journal | last1 = Malykh | first1 = AG | last2 = Sadaie | first2 = MR | title = Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | journal = Drugs | volume = 70 | issue = 3 | pages = 287–312 | year = 2010 | pmid = 20166767 | doi = 10.2165/11319230-000000000-00000}}</ref> | |||
| {{cite pmid | 20166767 }}</ref> | |||
| Several animal studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the ] of the ] drug family is still a matter of research. | Several animal studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the ] of the ] drug family is still a matter of research. | ||
| ==Clinical findings== | ==Clinical findings== | ||
| There has been put effort into investigation the possible use of oxiracetam as a medication to attenuate the symptoms of dementia. <ref name="Gouliaev" |
There has been put effort into investigation the possible use of oxiracetam as a medication to attenuate the symptoms of dementia. <ref name="Gouliaev"> | ||
| {{ cite pmid | 8061686 }}</ref> | |||
| However, no convincing results were obtained from studies where patients suffering from ] or organic solvent abuse were given 800 mg of the drug orally twice daily.<ref name="Gouliaev"/> | However, no convincing results were obtained from studies where patients suffering from ] or organic solvent abuse were given 800 mg of the drug orally twice daily.<ref name="Gouliaev"/> | ||
| Line 68: | Line 70: | ||
| ==See also== | ==See also== | ||
| *] | * ] | ||
| ==References== | ==References== | ||
Revision as of 22:45, 5 December 2011
Pharmaceutical compound | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.173  |
| Chemical and physical data | |
| Formula | C6H10N2O3 |
| Molar mass | 158.155 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Oxiracetam is a nootropic drug of the racetam family.
Several animal studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is still a matter of research.
Clinical findings
There has been put effort into investigation the possible use of oxiracetam as a medication to attenuate the symptoms of dementia. However, no convincing results were obtained from studies where patients suffering from Alzheimer's dementia or organic solvent abuse were given 800 mg of the drug orally twice daily.
The proven effects of the drug are limited to beneficial effects that lead to higher scores in tests for logical performance, attention, concentration, memory and spatial orientation. These tests were performed on patients with mild to moderate dementia, and the doses were 800-2400 mg orally twice a day for one to six months. Improvement has also been seen in patients with exogenic post-concussion syndrome, organic brain syndromes and other dementias. According to V. Gallai et al, oxiracetam is more effective than piracetam for this purpose.
Pharmacokinetics
Oxiracetam is well absorbed from the gastrointestinal tract with a bioavailability of 68-82% according to one source (E. Perucca et al) and 56% according to another. Peak serum levels are reached within one to three hours after a single 800 mg or 2000 mg oral dose, with the maximal serum concentration reaching between 19-31 µg/ml at these doses. Oxiracetam is mainly cleared renally and thus 84% is excreted unchanged in the urine. The half-life of oxiracetam in healthy individuals is about 8 hours, whereas it is 10-68 hours in patients with renal impairment. There is some penetration of the blood-brain barrier with brain concentrations reaching 5.3% of that in the blood (measured one hour after a single 2000 mg intravenous dose). Clearance rates range from 9 to 95 ml/min and steady-state concentrations when 800 mg is given twice daily range from 60 µM to 530 µM. The highest concentrations of oxiracetam is found in the septum pellucidum, followed by the hippocampus, the cerebral cortex and with the lowest concentrations in the striatum after a 200 mg/kg oral dose given to rats.
See also
References
-
Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20166767 , please use {{cite journal}} with
|pmid= 20166767instead. - ^
Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8061686 , please use {{cite journal}} with
|pmid= 8061686instead.
External links
| Racetams | |
|---|---|
| Racetams |
|
| Phenylpiracetams |
|
| Racetam-like |
|
| Psychostimulants, agents used for ADHD, and nootropics (N06B) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N06BA Centrally acting sympathomimetics | |||||||||
| N06BC Xanthine derivatives | |||||||||
| N06BX Other psychostimulants and nootropics | |||||||||
| |||||||||
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |